Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents

Gynecologic and Obstetric Investigation

Volumn 43, Issue 3, 1997, Pages 195-199

  Kigawa, Junzo ^a   Minagawa, Yukihisa ^a   Itamochi, Hiroaki ^a   Cheng, Xiusi ^a   Okada, Makoto ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Anticancer chemotherapy; Emesis; Granisetron; Methylprednisolone

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DOXORUBICIN; GRANISETRON; METHYLPREDNISOLONE; METOCLOPRAMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; VOMITING;

EID: 0030935724     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000291853     Document Type: Article

References (18)

1. Kigawa J. Minagawa Y. Ishihara H. Kanamori Y. Terakawa N: Tumor DNA ploidy and prognosis of patients with serous cystadenoearcino-ma of the ovary. Cancer 1993:72:804-808.
2. Kigawa J. Minagawa Y, Ishihara H, Itamochi II. Kanamori Y. Terakawa N: Retroperitoneal lymphadcncctomy including the paraaortic nodes in patients with stage III ovarian cancer. Am J Clin Oncol 1994:17:230-233.
3. Kris MG. Gratia RJ. Clark RA: Incidence, course, and sensitivity of delayed nausea and vomiting following the administration of high dose cisplatin. J Clin Oncol 1985:3:1379-1384.
4. Andrews PLR. Sanger GJ (eds): Emesis in Anti-Cancer Therapy: Mechanisms and Treatment. London. Chapman & Hall. 1992. pp 147-161.
5. Fredrikson M. Hursti T. Furst CJ. Borjcson S. Wikblom M. Peterson C: Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. BrJ Cancer 1992:65:779-780.
6. Oliver H. Wildcr-Smith G. Borgeat A. Chap-puis P, Fathi MBS, Forni M: Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993;72:2239-2241.
7. Cubcddu LX, Hoffmann IS: Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: Effects of antiemetics. J Clin Pharmacol 1993;33:691-697.
8. Barnes NM, Ge J. Jones WG, Naylor RJ. Rudd JA: Cisplatin induced emesis: Preliminary results indicative of changes in plasma levels of 5-hvdroxytrvptamine. Br J Cancer 1990:62: 862-864.
9. Cubeddu LX. Hoffmann IS. Fucnmayor NT. MalaveJJ: Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs. BrJ Cancer 1992:66:198-203.
10. Cubbeddu LX. Hoffmann IS. Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med 1990:322:810-821.
11. Rivierer A on behalf of the Granisctron Study Group: Dose finding study of granisctron in patients receiving high-dose cisplatin chemotherapy. BrJ Cancer 1994:69:967-971.
12. Aapro MS. Kirchner V, Tcrrcy JP: The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: The effect of graniselron. BrJ Cancer 1994;69:957-960.
13. Matera MG. Tullio MD. Lucarelli C, Casale F, Calabria C. Lampa E. Indolf P. Rossi F: Ondansetron. an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. J Med 1993: 24:161-171.
14. Torato M: Ondansetron plus dexamethasone: An effective combination in high dose cisplatin therapy. Eur J Cancer 1991 (suppl 27): 12-14.
15. Smith DB. Newland ES. Rustin GJS. Begent RH. Howell N, Mcquade B. Magshawe KD: Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin containing chemotherapy. Lancet 1991:338:487-490.
16. Kris MG. Baltzer LRN, Katherine M. Pisters W. Tyson LB: Enhancing the effectiveness of the specific serotonin antagonist. Cancer 1993: 72:3436-3442.
17. Kris MG. Gralla RJ. Tyson LB. Clark RA. Cir-rincionc C, Grashen S: Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and me-toclopramidc plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989:7:108-114.
18. Gebaucr A, Merger M. Kilbingcr H: Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Arch Pharmacol 1993; 347:137-140.